National Academies Press: OpenBook
« Previous: References
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

A
Study Activities

During the summer of 2008, officials from the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) approached the Institute of Medicine (IOM) about an examination of strategies for rare diseases research and orphan product development. Workshops organized by the IOM Forum on Drug Discovery, Development, and Translation in 2007 and 2008 had helped to sharpen ideas for an IOM study. As discussions progressed, the focus expanded beyond drugs and devices to include medical devices, including certain aspects of genetic tests. The charge to the IOM committee appointed to oversee the study was

To prepare a report that will assess existing strategies to promote research discoveries and development of orphan products to improve the health of people with rare diseases. To that end, the report will:

  1. Describe the epidemiology and societal impact of rare diseases and provide an overview of current methods for their prevention, diagnosis, and treatment.

  2. Describe the strengths and limitations of the current development pathways for new drugs, medical devices, and biologics for rare diseases (taking into account developments in genetic testing) and discuss the special challenges that rare diseases create for research and product regulation.

  3. Examine current public policies relevant to product development for rare diseases, including the Orphan Drug Act, the Humanitarian Use Device exemption, the approaches of the National Institutes of Health and the Food and Drug Administration, reimbursement policies, and other legislative and regulatory initiatives.

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
  1. Consider, as part of a national policy framework, a wide range of public and private strategies and innovations, such as:

    • enhancing multidisciplinary collaboration and government-university-industry partnerships in basic and translational research;

    • expanding public engagement and enhancing the roles of patient organizations;

    • facilitating research data and biomaterials collection and dissemination, including the use of bio-repositories and registries;

    • strengthening training of investigators;

    • disseminating information to clinicians, patients, and families;

    • revising policies and regulations;

    • encouraging alternative research financing mechanisms; and

    • developing research agendas and coordinating resources and development efforts throughout the product development pathways.

  1. Make recommendations for an integrated national rare disease policy on research and development, including responding to the proposals included in a white paper that will be prepared by the sponsors and provided to the committee approximately six months after the contract begins.

NIH and FDA concluded after further consideration that it was not feasible to present the white paper with proposals for the committee, but NIH and FDA staff made presentations to the committee and answered numerous committee questions. The committee reviewed a broad range of government, industry, and academic resources. It commissioned two background papers that appear as Appendixes B and C.

The study committee met five times between August 2009 and May 2010. Three of these meetings included public sessions during which the committee heard from a range of interested parties, including government officials, basic and clinical researchers, representatives of advocacy groups that are engaged in supporting research and product development, and representatives of industry trade associations and individual companies involved in developing drugs and devices. (The agendas for the public sessions follow this overview of study activities.) The committee also worked with the National Organization for Rare Disorders and the Genetic Alliance to solicit views from member organizations that are involved in research. (A list of organizations that submitted written statements follows the November meeting agenda below.)

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

INSTITUTE OF MEDICINECOMMITTEE ON ACCELERATING RARE DISEASES RESEARCH AND ORPHAN PRODUCT DEVELOPMENT

Room 204, Keck Center of the National Academies

500 Fifth Street, N.W., Washington, DC

August 12, 2009—Open Session

2:00

Welcome and introductions

 

Thomas Boat, M.D., Committee Chair

 

Sponsor objectives for study

 

Stephen Groft, Pharm.D, Director, NIH Office of Rare Diseases Research

Timothy R. Coté, M.D., M.P.H., Director, FDA Office of Orphan Products Development

3:00

Break

3:15

Discussion of background paper prepared by NIH and FDA

 

Stephen Groft, Pharm.D., Director, NIH Office of Rare Diseases Research

Timothy R. Coté, M.D., M.P.H., Director, FDA Office of Orphan Products Development

4:30

Adjourn open session

INSTITUTE OF MEDICINECOMMITTEE ON ACCELERATING RARE DISEASES RESEARCH AND ORPHAN PRODUCT DEVELOPMENT

Lecture Room, National Academy of Sciences Building

2101 C Street, N.W., Washington, DC

November 23, 2009—Open Session

8:20

Welcome and introductions

 

Thomas Boat, M.D., Committee Chair

8:30

Panel 1

 

National Organization for Rare Disorders

Wayne Pines, Consultant

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

 

Genetic Alliance

Sharon F. Terry, President and Chief Executive Officer

Discussion

9:10

Panel 2

 

Cystic Fibrosis Foundation Therapeutics, Inc.

Diana R. Wetmore, Ph.D., Vice President of Alliance Management

 

Multiple Myeloma Research Foundation and Multiple Myeloma Research Consortium

Susan Kelley, M.D., Chief Medical Officer

 

Friedreich’s Ataxia Research Alliance

Jennifer Farmer, M.S., Executive Director

 

Fanconi Anemia Research Fund (by phone)

Dave Frohnmayer, J.D., Co-founder and Board Vice President;

Lynn Frohnmayer, M.S.W., Co-founder and Advisor to the Board

10:10

Break

10:30

Discussion before and after break

11:00

Panel 3

 

Pharmaceutical Research and Manufacturers Association (PhRMA)

Alan Goldhammer, Ph.D., Vice President Scientific and Regulatory Affairs

 

Advanced Medical Technology Association (AdvaMed)

Susan Alpert, Ph.D., M.D., Senior Vice President, Global Regulatory Affairs, Medtronic, Inc.

 

Biotechnology Industry Organization (BIO)

Sara Radcliffe, M.P.H., Acting Executive Vice President, Health, and Vice President for Science and Regulatory Affairs

 

Discussion

Noon

Working lunch for committee and speakers and other invited guests

1:00

Panel 4

 

Mark L. Batshaw, M.D.

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

 

Principal Investigator, Urea Cycle Disorders Consortium (NIH Rare Diseases Clinical Research Network); Chief Academic Officer, Children’s National Medical Center; Chairman of Pediatrics and Associate Dean for Academic Affairs, George Washington University School of Medicine and Health Sciences

 

Frederick Kaplan, M.D.

Isaac & Rose Nassau Professor of Orthopaedic Molecular Medicine; Director, Center for Research in FOP (Fibrodysplasia Ossificans Progressiva) & Related Disorders, University of Pennsylvania School of Medicine

 

Alan K. Percy, M.D.

Principal Investigator, Angelman, Rett, and Prader-Willi Syndromes Consortium (NIH Rare Diseases Clinical Research Network); Medical Director, Civitan International Research Center; Professor of Pediatric Neurology, University of Alabama at Birmingham

 

Discussion

2:20

Open discussion

2:45

Adjourn open session

Organizations submitting written statements to the committee

In addition to the organizations presenting statements during the November meeting, the committee worked with the Genetic Alliance and the National Organization for Rare Disorders to solicit views from their members on issues before the committee. The following organizations responded:

American Partnership for Eosinophilic Disorders

Brown-Vialetto-Van Laere International

Children’s Tumor Foundation

FRAXA Research Foundation (Fragile X)

Genetic Alliance BioBank

International Rett Syndrome Foundation

NBIA Disorder Association (Neurodegeneration with Brain Iron Accumulation)

Pancreatic Cancer Action Network

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

INSTITUTE OF MEDICINECOMMITTEE ON ACCELERATING RARE DISEASES RESEARCH AND ORPHAN PRODUCT DEVELOPMENT

Lecture Room, National Academy of Sciences Building

2101 C Street, N.W., Washington, DC

February 4, 2010—Open Session

8:30

Welcome and introductions

 

Thomas F. Boat, M.D., Chair

 

Melissa Ashlock, M.D.

Senior Consultant, Therapeutics for Rare and Neglected Diseases Program, National Institutes of Health

 

Discussion

9:00

Update from FDA

 

Debra Lewis, O.D., M.B.A.

Associate Director, Office of Orphan Products Development, FDA

 

Introduction to Humanitarian Device Exemption (HDE) Process

Debra Lewis, O.D., M.B.A.

 

One Company’s Experiences and Perspectives with the HDE Process Nancy Hill

Vice President, Marketing and Business Development, Spirations, Inc.

 

Discussion

10:10

Break

10:30

Environment for Orphan Drug Development

 

Bernard Munos, M.B.A., Ph.D.

Advisor, Corporate Strategy, Eli Lilly and Company

 

Emil D. Kakkis, M.D., Ph.D.

President, Kakkis EveryLife Foundation

 

Discussion

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

11:30

Advances in Biomedicine: Exome Sequencing and Rare Diseases

 

Holly K. Tabor, Ph.D.

Assistant Professor, Treuman Katz Center for Pediatric Bioethics and Department of Pediatrics, University of Washington School of Medicine

 

Discussion

Noon

Working lunch for committee and speakers and other invited guests

 

Update from NIH

Stephen Groft, Pharm.D.

Director, Office of Rare Diseases Research, NIH

1:00

Translational and Clinical Research for Rare Diseases and Orphan Products

 

Christopher P. Austin, M.D.

Director, Chemical Genomics Center; Senior Advisor to the Director for Translational Research, National Human Genome Research Institute

 

Anne Pariser, M.D.

Medical Team Leader, Division of Gastroenterology Products and Inborn Errors of Metabolism, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

 

Discussion

2:00

Trial Design, Biomarkers, and Other Issues in Clinical Research for Rare Diseases and Orphan Products

 

William A. Gahl, M.D., Ph.D.

Clinical Director, National Human Genome Research Institute; Director, NIH Undiagnosed Diseases Program

 

Jennifer Van Eyk, Ph.D.

Professor of Medicine, Biological Chemistry, and Biomedical Engineering; Director, Johns Hopkins Bayview Proteomics Center, Johns Hopkins School of Medicine

 

Discussion

3:15

Open discussion

3:45

Adjourn open session

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×

This page intentionally left blank.

Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page283
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page284
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page285
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page286
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page287
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page288
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page289
Suggested Citation:"Appendix A: Study Activities." Institute of Medicine. 2010. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press. doi: 10.17226/12953.
×
Page290
Next: Appendix B: Innovation and the Orphan Drug Act, 1983-2009: Regulatory and Clinical Characteristics of Approved Orphan Drugs »
Rare Diseases and Orphan Products: Accelerating Research and Development Get This Book
×
Buy Paperback | $44.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!